---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-037525"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2024-12-16T23:59:59+00:00"
generated_at: "2026-05-29T02:56:32.886347+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Genprex completes Phase 1 dose escalation of Reqorsa + Tecentriq in ES-SCLC; Phase 2 opens

## Summary
- No dose-limiting toxicities observed; RP2D set at 0.12 mg/kg (highest dose tested).
- Safety Review Committee approved opening Phase 2 expansion; enrollment has started.
- Phase 2 will enroll ~50 patients at 10-15 U.S. sites; primary endpoint is 18-week PFS rate.
- Futility analysis after 25th patient reaches 18 weeks of follow-up.
- Acclaim-3 has FDA Fast Track and Orphan Drug designations for ES-SCLC.

## SEC filing metadata
- accession: 0001437749-24-037525
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2024-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774924037525/0001437749-24-037525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774924037525/gnpx20241205_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-037525
- JSON: https://secwatch.observer/filing/0001437749-24-037525.json
- Plain text: https://secwatch.observer/filing/0001437749-24-037525.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.